Eversept Partners, LP Adaptimmune Therapeutics PLC Transaction History

Eversept Partners, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.28 $315,324 - $540,556	-237,086 Closed	0 $0
Q1 2022 Nov 08, 2023	BUY	$1.73 - $4.06 $410,158 - $962,569	237,086 New	237,086 $488,000
Q1 2022 May 16, 2022	SELL	$1.73 - $4.06 $193,119 - $453,217	-111,630 Reduced 32.01%	237,086 $488,000
Q4 2021 Nov 08, 2023	SELL	$3.5 - $5.68 $336,598 - $546,251	-96,171 Reduced 21.62%	348,716 $1.31 Million
Q4 2021 Feb 14, 2022	SELL	$3.5 - $5.68 $336,598 - $546,251	-96,171 Reduced 21.62%	348,716 $1.31 Million
Q3 2021 Nov 08, 2023	BUY	$3.44 - $6.37 $1.53 Million - $2.83 Million	444,887 New	444,887 $2.3 Million
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $1.53 Million - $2.83 Million	444,887 New	444,887 $2.3 Million

123M

34.2K

16.3K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $73.5M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.